Health Care [ 11/12 ] | Biotechnology [ 55/73 ]
NASDAQ | Common Stock
Brainstorm Cell Therapeutics Inc. a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases.
The company's NurOwn proprietary cell therapy platform that leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function.
It is involved in the development of NurOwn, which has completed Phase IIIb clinical trial for the treatment of amyotrophic lateral sclerosis; Phase II clinical trial for the treatment of progressive multiple sclerosis; and for the treatment of alzheimer's disease, as well as for treatment of other neurodegenerative diseases.
Brainstorm Cell Therapeutics Inc. was incorporated in 2000 and is headquartered in New York, New York.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 12, 25 | -0.48 Decreased by -1.11 K% | -0.97 Increased by +50.09% |
| Mar 31, 25 | -0.51 Increased by +66.00% | -0.27 Decreased by -88.89% |
| Nov 5, 24 | -0.51 Decreased by -1.60 K% | -0.70 Increased by +27.14% |
| Aug 14, 24 | -0.04 Increased by +85.19% | -0.04 |
| Apr 1, 24 | -0.04 Increased by +71.43% | -0.07 Increased by +42.86% |
| Dec 31, 23 | -1.50 Decreased by -1.05 K% | -1.65 Increased by +9.09% |
| Nov 14, 23 | -0.03 Increased by +84.21% | -0.14 Increased by +78.57% |
| Aug 14, 23 | -0.27 Decreased by -42.11% | -0.15 Decreased by -80.00% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 25 | 0.00 Decreased by -100.00% | -2.86 M Increased by +15.79% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 24 | 0.00 Decreased by N/A% | -2.97 M Decreased by -142.50% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 24 | 0.00 Decreased by -100.00% | -2.71 M Increased by +49.18% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 24 | 365.00 K Increased by +173.44% | -2.54 M Increased by +49.77% | Decreased by -696.16% Decreased by -168.39% |
| Mar 31, 24 | 343.00 K Increased by +N/A% | -3.40 M Increased by +32.22% | Decreased by -991.55% Decreased by N/A% |
| Sep 30, 23 | 0.00 Decreased by -100.00% | -1.23 M Increased by +82.12% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 23 | 154.00 K Decreased by -24.51% | -5.33 M Increased by +24.31% | Decreased by -3.46 K% Decreased by -0.26% |
| Mar 31, 23 | -497.00 K Decreased by -246.18% | -5.06 M Increased by +5.62% | Increased by +1.02 K% Increased by +164.57% |